CSF2 and neoplasm: In low-immunogenic tumor models, the system elevated intratumoral levels of granulocyte–macrophage colony-stimulating factor (GM-CSF), promoted tumor regression, and induced systemic antigen-specific immune responses that suppressed the growth of distant, untreated tumors (Gurbatri et al. 2020).